Cancer and its complications contribute to patient suffering and costs for society. Identifying new treatments and more cost-effective surveillance strategies are essential.  In addition, there is a need for new approaches to preventing cancer, thereby reducing the number of patients, the burden of disease for individuals and society, and minimizing the clinical and economic consequences

HAMLET has been found to kill more than forty types of cancer cells, and Hamlet Pharma is exploring HAMLET’s potent capabilities against different cancer indications through clinical trials and collaborations, aiming towards licensing agreements with experienced partners.

Cancer Worldwide

More than 14 million new cancer cases that occur each year with an estimated mortality of about 8.2 million worldwide. The number of new cancer cases will rise to 25 million within the next two decades.

Cancer is the second leading cause of death globally and was responsible for 8.8 million deaths in 2015. Nearly one in six deaths is due to cancer.

Every third person develops some form of cancer.

Cancer in Sweden

In Sweden, 90,000 people are diagnosed with cancer annually.

One person is diagnosed with cancer every 10 minutes.

Based on IHE estimations from the Swedish Cancer Society, the number of new cancer cases is expected to increase from around 89,000 in 2013 to about 165,000 in 2040, which corresponds to an increase of 86%.

Costs of Cancer

The economic impact of cancer is significant and is increasing. The total annual economic cost of cancer in 2010 was estimated at approximately US$ 1.16 trillion.

In the US, total cancer costs were estimated at $206.3B in 2006, with estimated productivity losses of $17.9B for cancer-related morbidity and $110.2B for cancer-related mortality.

Cost of Cancer in Sweden

The total socioeconomic costs of cancer in 2013 amounted to SEK 36 billion. Based on the prognosis for the number of people with cancer, the socioeconomic costs of cancer could increase to SEK 44 billion by 2020, with a predicted further increase to over SEK 68 billion by 2040, assuming the 2013 price level.

The cost increase would correspond to a 90 percent increase in socio-economic costs by the year 2040. In comparison, the Swedish population is expected to grow to almost 12 million according to Statistics Sweden’s forecasts, or just over 20%.

Bladder Cancer Cost

Today, about 80,000 new cases of bladder cancer are expected to be diagnosed in 2017 in the US alone. While 430,000 new Bladder cancer cases were diagnosed in 2012 worldwide.

In the world, bladder cancer is the ninth most common cancer form and the sixth most common cancer in Sweden. The number of newly diagnosed cases of bladder cancer in Sweden is more than 3,000 per year.

In addition, the lifetime treatment costs per patient are very high due to frequent recurrences and a need for invasive monitoring.  Depending on the country, the lifetime cost per patient ranges from $96,000 to $202,000. British Colombia has the highest per patient treatment costs and the 5th highest overall cost. In the US alone, it was estimated at $3.4B annually with $2.9B in direct treatment-related costs, in 2006. A further increase occurred in 2012 when an estimated $4.1 billion was spent to treat bladder cancer. The diagnosis and care of bladder cancer thus represents a significant financial burden for patients and society, worldwide.

Given the aging population and the continued technological advances likely to occur over the next decade, such as new urinary markers for bladder cancer, improved endoscopy, and the evolving role of minimally invasive surgery, managing patients with bladder cancer will likely become even more costly than it is today. Thus, there will be growing pressure to contain costs and more efficiently manage care and societal resources.


  1. WHO. Who. [Online] February 2017.
  2. WILD, Edited by BERNARD W. STEWART and CHRISTOPHER P. World cancer report 2014. Lyon : International Agency for Research on Cancer, 2014.
  3. A Lundqvist, E Andersson, K Carlsson. KOSTNADER FÖR CANCER I SVERIGE IDAG OCH ÅR 2040. s.l. : IHE – Institutet för Hälso- och Sjukvårdsekonomi.
  4. 4. World health organisation . Cancer prevention and control in the context of an integrated approach. l. : World health organisation , 2016.
  5. American Cancer Society. American Cancer Society Cancer facts & figures. [Online]
  6. J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman, F. Bray. Cancer incidence and mortality worldwide. s.l. : International Journal of Cancer doi:10.1002/ijc.29210, 2014.
  7. Cancer fonden. [Online] 2017.
  8. The health economics of bladder cancer: a comprehensive review of the published literature. Botteman MF, Pashos CL, Redaelli A et al. s.l. : Pharmacoeconomics 21:1315–1330. , Vols. doi:10.2165/00019053-200321180-00003.
  9. Estimating health care costs related to cancer treatment from SEER-Medicare data. Brown ML, Riley GF, Schussler N et al. s.l. : Med Care 40:IV-104–IV-117. , 2002, Vols. doi:10.1097/00005650-200208001-00014.
  10. Cancer Prevalence and Cost of Care Projections. Cancer Prevalence and Cost of Care Projections. [Online]